108 related articles for article (PubMed ID: 12557438)
1. [Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies].
Radziwon P; Schenk JF; Mazgajska K; Boczkowska-Radziwon B; Galar M; Kłoczko J; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):308-11. PubMed ID: 12557438
[TBL] [Abstract][Full Text] [Related]
2. Tumor M2-PK levels in haematological malignancies.
Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
[TBL] [Abstract][Full Text] [Related]
3. [Levels of plasma TF and TFPI activities in patients with acute leukemia].
Zhu Y; Xie ZX; He XF; Han JZ; Li JC; He SL
Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):401-2, 405. PubMed ID: 12206017
[TBL] [Abstract][Full Text] [Related]
4. Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor.
Negaard HF; Iversen PO; Østenstad B; Iversen N; Holme PA; Sandset PM
Thromb Haemost; 2008 Jun; 99(6):1040-8. PubMed ID: 18521506
[TBL] [Abstract][Full Text] [Related]
5. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
[TBL] [Abstract][Full Text] [Related]
6. [Tissue factor and tissue factor pathway inhibitor during specific bronchial challenge in allergic asthma patients].
Kemona-Chetnik I; Bodzenta-Lukaszyk A; Kucharewicz I; Rogalewska AM
Przegl Lek; 2005; 62(2):98-101. PubMed ID: 16095153
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
Naumnik B; Borawski J; Chyczewski L; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
[TBL] [Abstract][Full Text] [Related]
9. [Examination of interleukin levels and growth factor from blood platelets in leukemia].
Kiersnowska-Rogowska B; Rogowski F; Petelski T; Citko A; Jaroszewicz E; Bielawiec M
Pol Tyg Lek; 1996 May; 51(19-22):281-2, 288. PubMed ID: 9289710
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study.
Bianco E; Marcucci F; Mele A; Musto P; Cotichini R; Sanpaolo MG; Iannitto E; De Renzo A; Martino B; Specchia G; Montanaro M; Barbui AM; Nieddu R; Pagano L; Rapicetta M; Franceschi S; Mandelli F; Pulsoni A;
Haematologica; 2004 Jan; 89(1):70-6. PubMed ID: 14754608
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques.
Migdalski A; Kotschy M; Jawien A
Eur J Vasc Endovasc Surg; 2005 Jul; 30(1):41-7. PubMed ID: 15933981
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
Saito M; Morishita E; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Matsuda T
Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
14. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor/its pathway inhibitor system and kynurenines in chronic kidney disease patients on conservative treatment.
Pawlak K; Tankiewicz J; Mysliwiec M; Pawlak D
Blood Coagul Fibrinolysis; 2009 Oct; 20(7):590-4. PubMed ID: 19491664
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
18. [The blood serum albumin transport function in patients with acute and chronic leukemias].
Litvinov AV; Savchenko VG; Tsepova EL; Chemodurova LN
Ter Arkh; 1998; 70(7):72-4. PubMed ID: 9742644
[TBL] [Abstract][Full Text] [Related]
19. [Changes of TF and TFPI activities in patients with hypertension or coronary atherosclerotic heart disease].
Xiao Z; Wang W; Han J; He X; Li J
Hunan Yi Ke Da Xue Xue Bao; 1999; 24(3):251-2, 255. PubMed ID: 12016797
[TBL] [Abstract][Full Text] [Related]
20. Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin in urological malignancies.
Perabo F; Sharma S; Gierer R; Wirger A; Fimmers R; Steiner G; Adam M; Schultze-Seemann W
Indian J Cancer; 2001 Mar; 38(1):1-7. PubMed ID: 14758878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
